Full Text View
Tabular View
Study Results
Related Studies
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
This study has been completed.
Study NCT00695955   Information provided by Takeda Global Research & Development Center, Inc.

First Received on June 10, 2008.   Last Updated on March 24, 2011   History of Changes
Results First Received: March 24, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil with or without add-on chlorthalidone
Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants enrolled at 39 investigative sites in Chile, Mexico and the United States from 22 June 2007 to 30 April 2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants with essential hypertension were enrolled in a once-daily (QD) treatment group.

Reporting Groups
  Description
Azilsartan Medoxomil

Cohort 1: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.

Cohort 2: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.

Participant Flow for 2 periods

 Period 1:   Cohort 1
    Azilsartan Medoxomil  
STARTED     362  
COMPLETED     260  
NOT COMPLETED     102  
Adverse Event                 26  
Protocol Violation                 2  
Lost to Follow-up                 30  
Withdrawal by Subject                 25  
Lack of Efficacy                 3  
Other                 16  

Period 2:   Cohort 2
    Azilsartan Medoxomil  
STARTED     307  
COMPLETED     203  
NOT COMPLETED     104  
Adverse Event                 24  
Protocol Violation                 5  
Lost to Follow-up                 38  
Withdrawal by Subject                 28  
Lack of Efficacy                 4  
Other                 5  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Azilsartan Medoxomil

Cohort 1: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.

Cohort 2: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.

Baseline Measures
    Azilsartan Medoxomil  
Number of Participants  
[units: participants]
 		  669  
Age, Customized  
[units: participants]
 		 
<45 years (Cohort 1)     81  
Between 45 and 64 years (Cohort 1)     233  
≥65 years (Cohort 1)     48  
<45 years (Cohort 2)     90  
Between 45 and 64 years (Cohort 2)     193  
≥65 years (Cohort 2)     24  
Gender, Customized  
[units: participants]
 		 
Female (Cohort 1)     173  
Male (Cohort 1)     189  
Female (Cohort 2)     144  
Male (Cohort 2)     163  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.   [ Time Frame: 56 weeks. ]
  Show Outcome Measure 1

2.  Primary:   Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.   [ Time Frame: 56 weeks. ]
  Show Outcome Measure 2

3.  Secondary:   Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.   [ Time Frame: 52 weeks ]
  Show Outcome Measure 3

4.  Secondary:   Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2   [ Time Frame: 52 weeks ]
  Show Outcome Measure 4

5.  Secondary:   Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.   [ Time Frame: 52 weeks. ]
  Show Outcome Measure 5

6.  Secondary:   Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.   [ Time Frame: 52 weeks. ]
  Show Outcome Measure 6


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Sr. VP, Clinical Science
Organization: Takeda Global Research and Development Center, Inc.
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com


No publications provided


Responsible Party: Sr. VP, Clinical Science, Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier: NCT00695955     History of Changes
Other Study ID Numbers: 01-05-TL-491-006, U1111-1113-8874
Study First Received: June 10, 2008
Results First Received: March 24, 2011
Last Updated: March 24, 2011
Health Authority: United States: Food and Drug Administration





Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services